American biotechnology company headquartered in Cambridge, Massachusetts, founded in Geneva in 1978 as Biogen N.V. and one of the oldest independent biotechnology companies. Develops and markets medicines for neurological and neurodegenerative disease including interferon beta and other multiple sclerosis therapies, nusinersen and tofersen for neuromuscular disease and aducanumab and lecanemab for Alzheimer's disease developed with Eisai, together with biosimilars, and runs manufacturing in the United States, Switzerland and Solothurn.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen